SCHEMBL3875798

SCHEMBL3875798

Cc1ccc(NCCO)c(C)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.60
MEN1 O00255 3/20 0.60
ALDH1A1 P00352 5/20 0.51
MAPT P10636 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
HTT P42858 2/20 0.51
KDM4E B2RXH2 3/20 0.50
HSD17B10 Q99714 2/20 0.50
RAPGEF4 Q8WZA2 1/20 0.47
TSHR P16473 1/20 0.46
MAPK1 P28482 2/20 0.45
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22677453 0.87 MAPT (0.54) KMT2AMEN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL11474259 0.84 GUCY1A1 (0.54) KMT2AMEN1ALDH1A1MAPTHTT
SCHEMBL11681121 0.83 KMT2A (0.55) KMT2AMEN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL10453656 0.83 SMN1; SMN2 (0.50) KMT2AMEN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL7176594 0.82 KMT2A (0.42) KMT2AMEN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL6515933 0.82 KDM4E (0.53) KMT2AMEN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL5271027 0.82 KMT2A (0.46) KMT2AMEN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL10476380 0.82 ALDH1A1 (0.56) KMT2AMEN1ALDH1A1MAPTHTT
SCHEMBL11333572 0.82 SMN1; SMN2 (0.49) KMT2AMEN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL1497919 0.81 HDAC6 (0.58) KMT2AMEN1ALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032622-A1 FAST-CURING CHEMICAL FASTENING SYSTEM AND USE THEREOF fischerwerke GmbH & Co. KG (DE) 2009-03-11 EP claimed
WO-2008000452-A1 FAST-CURING CHEMICAL FASTENING SYSTEM AND USE THEREOF FISCHERWERKE GMBH & CO. KG (DE) 2008-01-03 WO claimed
EP-0889933-A1 METHODS OF CURING UNSATURATED POLYMERS USING TERTIARY AROMATIC AMINE CURE PROMOTERS First Chemical Corporation (US) 1999-01-13 EP claimed
WO-1997035916-A1 METHODS OF CURING UNSATURATED POLYMERS USING TERTIARY AROMATIC AMINE CURE PROMOTERS FIRST CHEMICAL CORPORATION (US) 1997-10-02 WO claimed
CN-116947672-A Continuous preparation process of acetoacetanilide products 南通醋酸化工股份有限公司 2023-10-27 CN disclosed
CN-113165897-A Compositions and methods for purifying metals from steelmaking waste streams 里克希维亚有限公司 2021-07-23 CN disclosed
EP-3466920-A1 METHOD FOR OBTAINING -AMINO ALCOHOLS Universitat de València (ES) 2019-04-10 EP disclosed
EP-3365383-A1 SYNTHETIC FIXING SYSTEM CONTAINING VINYLESTER URETHANES SUCH AS URETHANE(METH)ACRYLATE BASED ON RENEWABLE RAW MATERIALS fischerwerke GmbH & Co. KG (DE) 2018-08-29 EP disclosed
EP-3344721-A1 CORROSION-INHIBITING, RADICALLY CUREABLE COMPOSITION Sika Technology AG (CH) 2018-07-11 EP disclosed
EP-3303438-A1 VINYL-TERMINATED PREPOLYMERS HAVING LOW VISCOSITY AND GOOD WATER SOLUBILITY Sika Technology AG (CH) 2018-04-11 EP disclosed
US-20160045528-A1 COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS ALIOS BIOPHARMA, INC. 2016-02-18 US disclosed
US-8044073-B2 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication TIBOTEC PHARMACEUTICALS (IE) 2011-10-25 US disclosed
EP-1379570-A1 VINYLESTER CARBAMIDE fischerwerke Artur Fischer GmbH & Co. KG (DE) 2004-01-14 EP disclosed
EP-1373429-A1 MULTI-COMPONENT KITS AND COMBINATIONS, USE THEREOF AND PLASTIC CEMENTS OBTAINED THEREFROM fischerwerke Artur Fischer GmbH & Co. KG (DE) 2004-01-02 EP disclosed
WO-2002079293-A1 VINYLESTER CARBAMIDE FISCHERWERKE ARTUR FISCHER GMBH & CO. KG (DE) 2002-10-10 WO disclosed
WO-2002079341-A1 MULTI-COMPONENT KITS AND COMBINATIONS, USE THEREOF AND PLASTIC CEMENTS OBTAINED THEREFROM FISCHERWERKE ARTUR FISCHER GMBH & CO. KG (DE) 2002-10-10 WO disclosed
EP-0589831-B1 Mortar and device for fixing of anchoring means in bore holes HILTI AG (LI) 1996-10-23 EP disclosed
EP-0589831-A1 Mortar and device for fixing of anchoring means in bore holes HILTI Aktiengesellschaft (LI) 1994-03-30 EP disclosed
US-4308190-A Dental materials based on organic plastics in paste form BAYER AKTIENGESELLSCHAFT (DE) 1981-12-29 US disclosed
US-4223138-A VAPORIZATION, CONDENSATION, RETARDING FLOW TO REACTION ZONE BAYER AKTIENGESELLSCHAFT (DE) 1980-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160045528-A1 COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS MAVS, EIF2AK2, SARS1 KMT2A 3332/4885MEN1 4014/4885ALDH1A1 2576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.